Chronic Lymphocytic Leukemia Therapeutics Market is Expanding Rapidly as AstraZeneca received the EU Clearance for its CLL Treatment Option Calquence

 

Chronic lymphocytic leukemia is a cancerous disease in which cancer cells begin to multiply in the lymph cells. CLL is aggressive cancer that invades the lymphatic system and attacks healthy cells of the immune system. It typically affects the lymph nodes and T cells, although it can also affect any other cells in the human body. The combination of chemotherapy is aimed at destroying cancer cells while at the same time allowing the body's immune system to restore the damaged cells. This allows for a more rapid response to the infection and better overall outcomes. As a result of this combination, chemotherapy is often used to treat several types of cancer at one time. It has been very successful in achieving results against most types of cancer. The targeted drugs are given to make the cancer cells unable to multiply and thus stop their growth.

Increasing prevalence of leukemia is expected to drive growth of the global chronic lymphocytic leukemia therapeutics market during the forecast period. According to the American Society of Clinical Oncology (ASCO), chronic lymphocytic leukemia (CLL) is the most common type of leukemia in adults aged 19 years and above with 37% of cases. According to the same source, around 21,040 new cases and 4,060 deaths are expected to occur in 2020 due to CLL in the U.S. Furthermore, according to the Leukemia & Lymphoma Society (LLC), in 2020, around 60,530 people are expected to be diagnosed with leukemia in the U.S. Such a high prevalence of CLL and leukemia has increased the demand for necessary therapeutics such as chemotherapy. Thus, these factors are expected to drive growth of the global chronic lymphocytic leukemia therapeutics market during the forecast period. Moreover, increasing geriatric population is expected to boost the global chronic lymphocytic leukemia therapeutics market growth over the forecast period.

However, high cost associated with treatment and stringent regulatory framework is expected to hinder the global chronic lymphocytic leukemia therapeutics market growth over the forecast period. Among regions, North America is expected to witness significant growth in the global chronic lymphocytic leukemia therapeutics market during the forecast period. This is owing to high incidence rate of CLL and the presence of key market players such as Amgen Inc., Incyte Corp, and Pfizer Inc. Furthermore, Asia Pacific is expected to register a robust growth rate over the forecast period, owing to increasing government initiatives.

Key players involved in the global chronic lymphocytic leukemia therapeutics market are Amgen Inc., Sanofi S.A., AstraZeneca plc, Pfizer Inc., Bristol-Myers Squibb Company, Novartis International AG, F. Hoffmann-La Roche Ltd, Johnson & Johnson, and Incyte Corp. 

For instance, in November 2020, AstraZeneca plc received the European Commission approval for ‘Calquence’, a next-gen Bruton’s tyrosine kinase (BTK) inhibitor indicated for adult patients with CLL.